A small double-blind crossover trial found that a single 600 mg dose of CBD significantly increased hippocampal glutamate levels in psychosis patients, with a corresponding decrease in symptom severity.
Readers interested in how CBD might work as an antipsychotic, particularly through mechanisms beyond the dopamine system.
600 mg CBD; p=0.035 glutamate increase
What the researchers found
Compared to placebo, CBD produced a significant increase in hippocampal glutamate (p=0.035) and a significantly greater decrease in symptom severity on the PANSS scale (p=0.032). A significant negative correlation existed between post-treatment symptom scores and glutamate levels (p=0.047), suggesting the glutamate increase may be linked to symptom improvement.
Why it matters
Understanding how CBD might work as an antipsychotic is crucial for developing new treatments. This study provides the first evidence linking CBD's effects on glutamate signaling to symptom improvement in psychosis patients.
The numbers in context
13 patients; 600 mg CBD single dose; hippocampal glutamate increase p=0.035; symptom severity decrease p=0.032; glutamate-symptom correlation p=0.047
How the study worked
Double-blind, randomized, placebo-controlled, repeated-measures, within-subject crossover design. 13 patients with psychosis received a single oral dose of CBD (600 mg) or placebo on separate days. Hippocampal glutamate measured via proton magnetic resonance spectroscopy.
What this study cannot tell us
Very small sample (13 patients). Single-dose design cannot show whether effects persist with repeated use. Within-subject crossover reduces confounders but limits generalizability.
How to read the evidence
Double-blind crossover RCT but very small sample (n=13) and single-dose design.
When this study was published
Published in 2021; part of an ongoing research program on CBD in psychosis.
The bigger picture
Most current antipsychotics target dopamine pathways. If CBD works through glutamate modulation, it represents a fundamentally different mechanism that could benefit patients who do not respond to existing treatments.
Questions still open
- Does repeated CBD dosing produce sustained changes in glutamate signaling? Would this mechanism apply across different stages of psychosis? How does this glutamate effect interact with conventional antipsychotic treatment?
Common questions
What is glutamate and why does it matter in psychosis?
Is CBD an antipsychotic?
Read the original research
Cannabidiol modulation of hippocampal glutamate in early psychosis.
Journal of psychopharmacology (Oxford, England), 35(7), 814-822
Citation
O'Neill, Aisling; Annibale, Luciano; Blest-Hopley, Grace; Wilson, Robin; Giampietro, Vincent; Bhattacharyya, Sagnik. (2021). Cannabidiol modulation of hippocampal glutamate in early psychosis.. Journal of psychopharmacology (Oxford, England), 35(7), 814-822. https://doi.org/10.1177/02698811211001107
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk